Recent Developments in Critical Genes in the Molecular Biology of Breast Cancer  by Sunpaweravong, Somkiat & Sunpaweravong, Patrapim
ASIAN JOURNAL OF SURGERY  VOL 28 • NO 1 • JANUARY 2005 71
070/2001
Review Article
© 2005 Elsevier. All rights reserved.
Introduction
Breast cancer is the most common malignancy among females
worldwide and its incidence is increasing with every year.
Although there have been improvements in early diagnosis,
surgical techniques, adjuvant hormone therapy, chemotherapy
and radiotherapy, this disease is still a leading cause of cancer
mortality.
Growing knowledge of breast cancer biology is having a
great impact on clinical management in such varied fields as
determining the lifetime risk of cancer, prognosis and re-
sponse to treatment. In addition, increased understanding of
breast cancer pathways is leading to a new field of biological
targeted therapy, heralding a new era in cancer treatment. We
conducted this literature review focusing on the role of critical
genes including BRCA1, BRCA2, HER2 and p53 in breast cancer
development and their clinical implications.
Familial breast cancer genes BRCA1 and
BRCA2
Hall et al1 reported in 1990 that the BRCA1 gene is located on
chromosome 17, and Wooster et al2 reported in 1994 that the
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BRCA2 gene is located on chromosome 13. Both genes encode
potential tumour suppressing proteins, but in contrast to
many genes involved in hereditary cancer syndromes, BRCA1
and BRCA2 are not mutated in sporadic breast cancer. Both
genes maintain genomic stability through their involvement
in homologous recombination and in repair of transcription-
coupled and double-strand breaks; they are transmitted
through autosomal dominant inheritance.3
Germline mutations in BRCA1 and BRCA2 relate to famil-
ial breast and ovarian cancers. They have been estimated to
account for 5–10% of all breast cancers and approximately
65% of hereditary cases (40% related to BRCA1 and 25% to
BRCA2).4,5 The cumulative risk of breast cancer with a muta-
tion in BRCA1 or BRCA2 is approximately 3% by age 30 years,
19% by age 40, 51% by age 50, 54% by age 60, and 85% by age
70.6 Familial characteristics related to a high incidence of BRCA
mutation include:7 two or more family members with breast
cancer before the age of 50 years; a family history of both breast
and ovarian cancers; and a family history of male breast cancer.
Guidelines for a surveillance programme for women with
a BRCA mutation are:8 monthly breast self-examination from
age 18; clinical examination every 6 months from age 25; and
yearly mammogram from age 25.
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Since young women have dense breast tissue, magnetic
resonance imaging (MRI) is more sensitive than mammo-
graphy.9,10 The prospective Dutch MRI Screening Study
(MRISC) showed that the relative sensitivity of MRI was 83%
and of mammography was 26%; the specificity of mammogra-
phy was 95% and of MRI was 88%.11 Because MRI is too
expensive to be used for routine screening, it should be consid-
ered only in selected cases.
BRCA1 and BRCA2 breast cancers usually show a high
grade and p53 over-expression. Prophylaxis with tamoxifen is
expected to reduce the incidence of primary breast cancer in
BRCA carriers. Tamoxifen is effective in reducing cancer in the
contralateral breast by 75% in BRCA1 and BRCA2 breast can-
cers.12 This oestrogen receptor (ER) modulator does not help
when its use is started at the age of 35 years or more or in
oestrogen-receptor negative breast cancers.13 Combined data
from several series found that 83% of BRCA1 breast cancer
tumours were ER-negative, whereas 76% of BRCA2 breast
tumours were ER-positive.14 Since tamoxifen has side effects
such as venous thromboembolism, endometrial cancer and
cataracts,15 there is a need for more well-designed clinical trials
to define the most effective endocrine agent, the optimal dura-
tion of treatment, and age at which to begin chemoprevention.
Prophylactic mastectomy, the most effective prevention,
has been reported to be at least 90% effective in reducing breast
cancer incidence in women with BRCA mutations.16,17 Pro-
phylactic oophorectomy can prevent ovarian cancer and de-
crease the incidence of breast cancer by 50% in BRCA carri-
ers.18,19 Women considered eligible for bilateral prophylactic
oophorectomy are older than 35 years and have completed
childbearing. However, we should remain aware of the fact
that breast cancer does not develop in all BRCA1 and BRCA2
mutation carriers, and early detection and treatment is still a
valid option for the individual.
Oncogene HER2
The gene for the human epidermal growth factor receptor
(EGFR) HER2, also known as c-erbB-2 or HER2/neu, is located
on chromosome 17. HER2 is a member of the EGFR family of
tyrosine kinases, which also includes HER1, HER3 and HER4.
Epidermal growth factors stimulate cell proliferation, prevent
apoptosis and stimulate angiogenesis and metastasis via EGFR-
related pathways (Figure 1). The receptors are composed of
three domains: an extracellular ligand-binding domain, a trans-
membrane lipophilic region, and an intracellular protein tyro-
sine kinase domain. HER2 is a key component for regulating
cell growth. However, when the HER2 protein is over-expressed,
it increases cell growth and reproduction.3
Immunohistochemical (IHC) staining has been approved
as a screening method for HER2 protein activity. An IHC score
of 3+ indicates a high level of expression whereas a 2+ score
requires gene status confirmation by fluorescence in situ
hybridization. HER2 is over-expressed in 25–30% of primary
breast cancers and is associated with shorter survival, higher
recurrence rates and lower response to chemotherapy and
hormone therapy.20–23 Anthracycline-based regimens appear
to be more beneficial than CMF (cyclophosphamide, meth-
otrexate and fluorouracil) regimens in this patient group.
Trastuzumab is a recombinant DNA-derived humanized
monoclonal antibody that selectively binds to the extracellu-
lar domain of HER2. This specific biological drug has been
approved in the USA since 1998 for HER2-positive patients
with metastatic breast cancer. It is recommended that
trastuzumab be combined with chemotherapy, although it is
also effective when used alone. Recent clinical studies have
tried to determine the role of trastuzumab in adjuvant and
neoadjuvant therapy in breast cancer patients who over-
express HER2. The drug is generally well tolerated but
cardiotoxicity has been reported in 4% of cases when the drug
is used alone. This incidence is increased to 27% with
trastuzumab in combination with anthracycline and cyclo-
phosphamide compared with 8% with anthracycline and cy-
clophosphamide alone.24,25 However, this cardiotoxicity dif-
fers from anthracycline cardiotoxicity in that there is no evi-
dence of cumulative dose toxicity, it is less severe, and the
deleterious effects are often reversible.26–28
Figure 1. Mechanism of action of epidermal growth factors (EGF) in
cancer.
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Evaluation of HER2 expression should be considered a
routine workup in all breast cancers because of its effects on
survival (prognostic factor), response to treatment (predictive
factor) and therapeutic role.
Tumour suppressor gene p53
p53, located on chromosome 17, was the first gene to be
identified as a mutant in tumours, in 1979.29 p53 is a nuclear
phosphoprotein important in cell cycle regulation, repairing
DNA damage, apoptosis to eliminate and inhibit the prolif-
eration of abnormal cells, and inhibition of angiogenesis
(Figure 2). Mutations in p53 occur in 20–40% of sporadic
breast cancers.30–34
Two different methods have been used to assess p53
alterations: DNA sequencing and IHC. Most p53 alterations
found in breast cancers are point mutations leading to the
synthesis of a stable, malfunctioning and non-degradable
protein that accumulates in tumour cells, and thus can be
detected by IHC. Studies that have used sequencing showed
a stronger association to survival than those using IHC.35
The incidence of p53 mutations varies among populations
and stages. The incidence in node-negative patients is lower
than that in node-positive patients, and large tumours and
tumours in patients with advanced disease have a higher
incidence of mutations than small tumours. The prevalence
of p53 mutations in recurrent tumours is higher than that
in primaries, and younger patients seem to have a higher
frequency.36
A meta-analysis of the association between p53 mutation
and clinical prognostic outcome of breast cancer showed a
poorer overall outcome and disease-free survival rates. The
relative hazard (RH) of dying in unselected patients was 2.0
(95% confidence interval, CI, 1.7–2.5). For node-negative
patients, the RH was 1.7 (95% CI, 1.2–2.3), and for node-
positive patients, it was 2.6 (95% CI, 1.7–3.9).37
Many studies have shown a correlation between the p53
mutation and response to treatment. Locoregional radio-
therapy improves survival in breast cancer cases with p53
mutations but not in those with the wild type. Studies of
locally advanced breast cancers, treated with doxorubicin as
neoadjuvant therapy, showed that the p53 mutation was a
predictor of primary drug resistance and early relapse.38,39
Among patients with advanced disease, p53 mutation carriers
have a poor response to tamoxifen or FEC (fluorouracil,
epirubicin and cyclophosphamide), but a better response to
paclitaxel-based treatment.40,41
The p53 gene itself has also been used in gene therapy for
p53-mutated cancer patients. There are many clinical trials
under way, including some ongoing phase III studies in many
cancers such as head and neck, lung, ovarian, hepatobiliary
and breast cancer. Preliminary results suggest that p53
gene therapy may become a new modality for cancer treat-
ment.42–46
Conclusion
BRCA genes correlate with familial breast cancer and deter-
mine the risk of breast cancer development. Over-expression
of HER2, an oncogene, indicates a poor outcome and response
to treatment. The antibody to the HER2 receptor is used as
treatment in advanced breast cancers. p53 is a well-known
tumour suppressor gene and mutations in p53 also predict
prognosis and response to treatment.
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